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Abstract
Introduction:  It  is  difﬁcult  to  evaluate  the  effect  of  drugs  clinically  used  for  idiopathic  sud-
den sensorineural  hearing  loss,  mainly  because  the  underlying  mechanism  of  it  has  remained
unknown.
Objective: This  study  assessed  the  efﬁcacy  of  hyperbaric  oxygen  therapy  or  ozone  therapy  in
the treatment  of  idiopathic  sudden  sensorineural  hearing  loss,  when  either  therapy  was  included
with steroid  treatment.
Methods:  A  retrospective  analysis  examined  106  patients  with  idiopathic  sudden  sensorineural
hearing loss  seen  between  January  2010  and  June  2012.  Those  with  an  identiﬁed  etiology  were
excluded. The  patients  were  divided  into  three  treatment  groups:  oral  steroid  only  (n  =  65),
oral steroid  +  hyperbaric  oxygen  (n  =  26),  and  oral  steroid  +  ozone  (n  =  17).  Treatment  success
was assessed  using  Siegel  criteria  and  mean  gains  using  pre-  and  post-treatment  audiograms.
Results:  The  highest  response  rate  to  treatment  was  observed  in  the  oral  steroid  +  ozone  therapy
group (82.4%),  followed  by  the  oral  steroid  +  hyperbaric  oxygen  (61.5%),  and  oral  steroid  groups
(50.8%). There  were  no  signiﬁcant  differences  in  the  response  to  treatment  between  the  oral
steroid and  oral  steroid  +  hyperbaric  oxygen  groups  (p  <  0.355).  The  oral  steroid  +  ozone  group
showed a  signiﬁcantly  higher  response  rate  to  treatment  than  the  oral  steroid  group  (p  =  0.019).
There were  no  signiﬁcant  differences  between  the  oral  steroid  +  hyperbaric  oxygen  and  oral
steroid +  ozone  groups  (p  =  0.146).
Conclusion:  The  efﬁciency  of  steroid  treatment  in  patients  with  severe  hearing  loss  was  low.  It
was statistically  ascertained  that  adding  hyperbaric  oxygen  or  ozone  therapy  to  the  treatment
contributed  signiﬁcantly  to  treatment  success.
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O  papel  da  oxigenoterapia  hiperbárica  e  da  ozonioterapia  na  surdez  súbita
Resumo
Introduc¸ão:  É  difícil  avaliar  o  efeito  dos  fármacos  clinicamente  utilizados  na  surdez  Súbita
Idiopática SS,  principalmente  porque  o  mecanismo  subjacente  de  PANSSI  manteve-se  descon-
hecido.
Objetivo: Este  estudo  avaliou  a  eﬁcácia  da  Oxigenoterapia  Hiperbárica  (OHB)  ou  ozonioterapia
no tratamento  de  surdez  súbita,  quando  uma  ou  outra  terapia  foi  incluída  no  tratamento  com
esteroides.
Método: Uma  análise  retrospectiva  examinou  106  pacientes  com  surdez  súbita  atendidos  entre
janeiro de  2010  e  junho  de  2012.  Aqueles  com  uma  etiologia  identiﬁcada  foram  excluídos.
Os pacientes  foram  divididos  em  três  grupos  de  tratamento:  apenas  esteroide  oral  (n  =  65),
esteroide  por  via  oral  +  OHB  (n  =  26)  e  esteroides  por  via  oral  +  ozônio  (n  =  17).  O  sucesso  do
tratamento  foi  avaliado  usando  critérios  de  Siegel  e  os  ganhos  médios  usando  audiogramas  pré
e pós-tratamento.
Resultados:  a  taxa  de  resposta  mais  elevada  para  o  tratamento  foi  observada  no  grupo
de esteroide  +  ozonioterapia  (82,4%),  seguida  por  grupos  de  esteroide  oral  +  OHB  (61,5%)  e
esteroide oral  (50,8%).  Não  houve  diferenc¸as  signiﬁcativas  na  resposta  ao  tratamento  entre
os grupos  de  esteroide  oral  e  esteroides  +  OHB  (p  <  0,355).  O  grupo  de  esteroide  oral  +  ozônio
apresentou  uma  taxa  de  resposta  signiﬁcativamente  mais  elevada  ao  tratamento  do  que  o  grupo
de esteroide  oral  (p  =  0,019).  Não  houve  diferenc¸as  signiﬁcativas  entre  os  grupos  de  esteroide
oral +  OHB  e  esteroide  oral  +  ozônio  (p  =  0,146).
Conclusão:  A  eﬁciência  do  tratamento  com  esteroides  em  pacientes  com  perda  auditiva  grave
foi baixa.  Veriﬁcou-se  estatisticamente  que  a  adic¸ão  de  OHB  ou  ozonioterapia  ao  tratamento
contribuiu  signiﬁcativamente  para  o  sucesso  do  tratamento.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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University,  between  January  2010  and  June  2012.  The  inclu-ntroduction
diopathic  sudden  sensorineural  hearing  loss  (ISSNHL)  is  an
tologic  disease  requiring  urgent  diagnosis  and  treatment.
SSNHL  is  commonly  deﬁned  as  hearing  loss  of  more  than
0  dB,  affecting  three  or  more  frequencies,  arising  over  less
han  3 days,  without  an  identiﬁable  etiology.1 The  hearing
oss  develops  within  a  few  seconds,  minutes,  or  hours.  In
everal  epidemiological  studies  conducted  on  the  incidence
f  ISSNHL,  the  spontaneous  recovery  rate  of  ISSNHL  is  high;
he  actual  incidence  is  estimated  to  be  far  above  this  value.
Although  several  factors  account  for  its  etiology,  most
ases  are  idiopathic.  Although  there  are  more  than  100  con-
idered  etiologic  causes,  the  widely  accepted  etiological
heories  are  viral  infections,  vascular  causes,  cochlear  mem-
rane  disorders,  and  autoimmunity.  In  many  cases,  however,
o  apparent  cause  can  be  indicated.2--4 The  etiology  can  be
lariﬁed  in  10--15%  of  cases,  with  ISSNHL  diagnosed  in  the
emainder.2,4,5
Although  ISSNHL  recurs  spontaneously  in  32--65%  of
ases,6 the  reported  rate  ranged  between  49%  and  89%
hen  steroids  were  used  during  treatment.7 Steroids  remain
he  most  commonly  used  medication  for  the  treatment  of
SSNHL.
The  idea  that  ISSNHL  could  occur  due  to  hypoxia  in
he  cochlear  apparatus  makes  hyperbaric  oxygen  therapy
HBOT)  a  reasonable  choice.  Generally,  HBOT  is  recom-
ended  for  the  treatment  of  ISSNHL  as  a  supplementary
herapy  to  the  ﬁrst-line  medical  treatment.
s
T
lRecently,  ozone  therapy  has  been  used  as  a  supplemen-
ary  treatment  for  diseases  where  inﬂammatory  processes
re  preponderant  and  an  ischemic  etiology  is  found.  Ozone
herapy  is  considered  a  treatment  for  ISSNHL  because  its
ffects,  such  as  enhancing  oxygen,  glucose,  and  adenosine
riphosphate  (ATP)  delivery  to  ischemic  tissues,  in  turn  pro-
ucing  reactive  oxygen  derivatives,  result  in  vasodilation  by
ncreasing  the  amount  of  nitric  oxide,  stimulating  angiogen-
sis  and  providing  immunomodulation.
Our  study  included  106  patients  with  ISSNHL  who  were
reated  at  our  clinic  between  2010  and  2012.  We  retrospec-
ively  investigated  the  efﬁcacy  of  the  treatment  protocols
pplied  to  patients  with  ISSNHL,  and  studied  the  role  of
BOT  or  ozone  therapy  for  the  treatment  of  ISSNHL  with
ither  therapy  administered  as  a  supplement  to  systemic
teroid  treatment.
ethods
atients
 retrospective  chart  review  was  performed  106  patients
ith  a  diagnosis  of  ISSNHL  who  presented  at  the  Department
f  Otorhinolaryngology  --  Head  and  Neck  Surgery  at  Akdenizion  criteria  were  the  same  for  each  group  of  treatment.
he  inclusion  criteria  were  unilateral  sensorineural  hearing
oss  with  an  average  hearing  loss  of  30  dB  in  consecutive
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The  role  of  hyperbaric  oxygen  and  ozone  in  sudden  hearing  
frequencies  developing  within  3  days.  Pediatric  patients,
patients  with  preexisting  Meniere’s  disease,  tumors,  acous-
tic  trauma,  barotrauma,  retrocochlear  disease,  bilateral
hearing  loss,  those  with  a  history  of  chronic  otitis  in  the
same  ear,  and  those  with  a  history  of  surgery  of  the  same
ear  were  not  included  in  the  study.  Those  patients  with  an
identiﬁed  cause  were  excluded,  and  only  idiopathic  cases
were  investigated.  Bilateral  cases  were  also  not  included.
In  all,  62  (58.5%)  of  the  study  participants  were  male  and  44
(41.5%)  were  female.  The  mean  age  was  50  ±  13  years;  the
oldest  person  was  81  years,  whereas  the  youngest  person
was  17  years.  All  of  the  patients  had  repeated  audiological
tests  on  the  ﬁrst,  third,  ﬁfth,  seventh,  and  ﬁfteenth  days
of  treatment.  In  accordance  with  the  American  Speech  and
Hearing  Association  guidelines,  hearing  loss  was  classiﬁed
as  mild  (26--40  dB),  moderate  (41--55  dB),  moderate-severe
(56--70  dB),  severe  (71--90  dB),  and  profound  or  total  (91  dB
and  above)  loss  according  to  the  average  pure  tone
thresholds  at  500,  1000,  2000,  and  4000  Hz.  Temporal
magnetic  resonance  imaging  was  requested  for  all  of
the  patients  to  evaluate  the  acoustic  channel  and  brain
stem.
Treatment  groups
The  patients  were  divided  into  three  groups  according  to  the
treatment  protocol  received:  oral  steroid  (Group  A),  oral
steroid  +  HBOT  (Group  B),  and  oral  steroid  +  ozone  (Group
C).  The  oral  steroid  group  comprised  63  patients,  the  oral
steroid  +  HBOT  group  comprised  26  patients,  and  the  oral
steroid  +  ozone  group  comprised  17  patients.  According  to
our  clinic’s  protocols  for  ISSNHL  with  oral  steroids,  all  of
the  patients  were  given  1  mg/kg/day  oral  prednisolone  for
5  days,  the  maximum  dose  given  to  patients  was  60  mg/day,
which  was  subsequently  tapered  by  10  mg  every  2  days;  at
the  same  time,  30  mg/day  gastroprotective  oral  lansopra-
zole  and  a  salt-free  diet  combination  were  administered.
The  oral  steroid  treatment  is  done  for  all  the  patients  rou-
tinely.  During  the  past  6  years,  hyperbaric  oxygen  therapy
and  ozone  therapy  has  been  applied  as  adjunctive  treat-
ment  in  our  clinic  for  ISSNHL.  Since  then,  we  have  given
information  and  recommend  about  the  ozone  therapy  and
hyperbaric  oxygen  treatment.  And  if  the  patient  want  one
of  these  treatments;  this  treatment  add  to  the  steroid
treatment.  Since  the  hyperbaric  oxygen  therapy  and  ozone
therapy  which  are  supplementary  treatment  methods  to  the
routine  treatments,  are  not  paid  for  by  the  insurance  com-
panies  in  our  country,  none  of  our  patients  could  receive
these  treatments.
The  socio-economic  and  transportation  status  was  inﬂu-
ential  in  choosing  the  treatment  method.  The  reason  for
the  number  of  the  patients  who  received  hyperbaric  oxygen
therapy  and  ozone  therapy  being  few  stems  from  the  fact
that  not  all  patients  accept  this  treatment  because  it  has  a
fee  to  be  paid.
The  patients  in  the  oral  steroid  +  HBOT  group,  in  addition
to  receiving  oral  steroids  according  to  the  ISSNHL  proto-
col,  received  HBOT  applied  as  100%  oxygen  inhalation  at  2.5
ATA  pressure  for  90  min,  which  was  administered  once  a  day
within  a  10  day  period  (Hiperbot  Model  101;  Hiperbot  Ltd,
Istanbul).
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The  patients  in  the  oral  steroid  +  ozone  group,  in  addition
o  receiving  oral  steroids  according  to  the  ISSNHL  protocol,
eceived  medical  ozone  therapy  using  the  major  autohe-
otherapy  method.  In  this  method,  an  anti-ozonant  infusion
et  (Ozonosan;  Mikro-Perl-System;  Dr.  J.  Hänsler,  Iffezheim,
ermany)  and  100  mL  blood  drawn  from  the  patient  were
ixed,  under  sterile  conditions,  with  99.5%  oxygen  and
.5%  of  an  ozone  mixture  (the  ozone  concentration  within
he  mixture  =  20  g/mL)  obtained  from  an  ozone  generator
Medozon  Compact;  Herrmann  Apparatebau,  Kleinwallstadt,
ermany);  this  blood  mixture  was  again  administered  to  the
atient  intravenously,  at  least  for  a  5-min  period.  During  the
ourse  of  the  process,  sodium  citrate  was  used  as  an  antico-
gulant.  This  therapy  was  performed  in  ﬁve  sessions  twice
 week.  The  ozone  therapy  protocol  that  used  by  Ragab
nd  his  friends  on  their  search  about  this  topic;  also  used
s  source  (Ragab  A,  Shreef  E,  Behiry  E,  Zalat  S,  Noaman
.  Randomised,  double  blinded,  placebo-controlled,  clinical
rial  of  ozone  therapy  as  treatment  of  sudden  sensorineural
earing  loss.  J  Laryngol  Otol.  2009;123:54--60).
udiometric  investigation
o  determine  the  change  in  post-treatment  hearing,  pre-
reatment  audiological  examination  and  post-treatment
udiological  examination  were  performed  on  the  ﬁfteenth
ay  (the  threshold  averages  at  500,  1000,  2000,  and  4000  Hz
ere  compared)  (Clinical  Audiometers  AC-40  Interacoustics,
ssens,  Denmark).
The  results  were  evaluated  considering  changes  in  Speech
iscrimination  Scores  (SDSs)  and  Pure  Tone  Averages  (PTAs)
t  500,  1000,  2000,  and  4000  Hz.
The  response  to  therapy  was  categorized  according  to
iegel’s  criteria8 as  follows:
.  Healing:  ﬁnal  threshold  more  than  25  dB.
.  Partial  improvement:  gain  of  more  than  15  dB,  ﬁnal  hear-
ing  threshold  25--45  dB.
.  Slight  improvement:  gain  of  more  than  15  dB,  ﬁnal  hear-
ing  threshold  more  than  45  dB.
.  No  response:  gain  of  less  than  15  dB  and  ﬁnal  hearing
threshold  more  than  75  dB.
A  PTA  greater  than  15  dB  was  considered  a  response  to
reatment,  whereas  a  PTA  less  than  15  dB  was  deemed  no
esponse  to  treatment.  If  the  increase  in  the  pre-  vs.  post-
reatment  SDS  of  the  patients  was  more  than  20%,  the  value
as  considered  a  response  to  treatment;  however,  if  the
ncrease  was  less  than  20%,  the  value  was  considered  no
esponse  to  treatment.
The  audiograms  were  classiﬁed  as  upsloping,  downslop-
ng,  ﬂat,  and  total  deafness  according  to  the  hearing
hresholds  at  different  frequencies.  An  upsloping  curve  was
eﬁned  as  a  more  severe  (>20  dB)  hearing  loss  at  low  (250
nd  500  Hz)  frequencies,  whereas  a  downsloping  curve  was
eﬁned  as  a  more  severe  (>20  dB)  hearing  loss  at  high  (4000
nd  8000  Hz)  frequencies.  An  audiometric  curve  with  no
ore  than  15  dB  difference  at  any  frequency  was  accepted
s  being  ﬂat.
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Table  1  The  classiﬁcation  of  the  initial  hearing  loss  degrees  of  the  groups.
Group  Mild  Moderate  Moderate-severe  Severe  Profound  or  total
A  3  (4.8%)  10  (15.9%)  15  (23.8%)  14  (22.2%)  21  (33.3%)
B 1  (3.8%)  4  (15.4%)  2  (7.7%)  4  (15.4%)  15  (57.7%)
C 0  3  (17.6%)  2  (11.8%)  2  (11.8%)  10  (58.8%)
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oA, oral steroid group; B, oral steroid + hyperbaric oxygen group; C
tatistical  analysis
ll  statistical  analyses  were  performed  using  the  Statistical
ackage  for  the  Social  Sciences  (SPSS)  for  Windows  7.0  PASW
tatistics  18  (SPSS,  Chicago,  IL,  USA).  A  two-tailed  t-test  was
sed  for  descriptive  statistical  analysis  (mean  ±  standard
eviation)  of  quantitative  data.  A  p-value  of  <0.05  was  con-
idered  to  indicate  statistical  signiﬁcance.
The  university  ethics  council  approved  this  study
05/02/2013.  Decision  n◦ 43).  Our  study  was  performed  as
etrospectively.  We  have  started  to  do  hyperbaric  oxygen
herapy  and  ozone  therapy  on  our  clinic  since  2010  for  the
atients  who  had  sudden  sensorineural  hearing  loss.  We  con-
ucted  the  study  in  2013  retrospectively  and  those  patients
hom  we  followed-up  and  treated  from  2010  to  2012  were
ncluded  in  the  study.  Because  of  this  our  ethics  board
pproval  was  dated  2013.
esults
roups
n  total,  106  patients  who  complied  with  the  participa-
ion  criteria  of  the  study  were  selected.  The  cases  in  the
resent  study  were  divided  into  three  groups  as  follows:  63
atients  with  oral  steroid  treatment  (Group  A),  26  patients
ith  oral  steroid  +  HBOT  (Group  B),  and  17  patients  with  oral
teroid  +  ozone  therapy  (Group  C).  No  statistically  signiﬁcant
ifference  was  found  among  the  groups  regarding  age  and
ex.
TA
hen  the  initial  pre-treatment  PTAs  (PTPTAs)  of  the  patients
ere  analyzed,  the  average  of  all  study  participants  was
5.8  dB.  By  group,  the  values  were  80.7  dB  in  Group  A,
2.02  dB  in  Group  B,  and  94.9  dB  in  Group  C.  No  statisti-
ally  signiﬁcant  difference  was  observed  among  the  groups
p  = 0.084)  in  Kruskal--Wallis  tests  (Table  1).
t
s
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Table  2  The  groups’  response  rates  to  treatment  according  to  si
Group  Complete  recovery  Partial  recovery  
A  14  (22.2%)  10  (15.9%)  
B 3  (11.5%)  4  (15.4%)  
C 3  (17.6%)  4  (23.5%)  
A, oral steroid group; B, oral steroid + hyperbaric oxygen group; C, oral steroid + ozone group.
esponse  to  treatment
hen  the  groups  were  analyzed  using  Siegel’s  criteria
ccording  to  their  recovery  levels,  Group  A  showed  complete
ecovery  in  14  (22.2%)  cases,  partial  recovery  in  10  (15.9%)
ases,  weak  recovery  in  8  (12.7%)  cases,  and  no  recovery
n  31  (49.2%)  cases.  Group  B  demonstrated  complete  recov-
ry  in  3  (11.5%)  cases,  partial  recovery  in  4  (15.4%)  cases,
eak  recovery  in  9  (34.6%)  cases,  and  no  recovery  in  10
38.5%)  cases.  In  Group  C,  complete  recovery  was  observed
n  3  (17.6%)  cases,  partial  recovery  in  4  (23.5%)  cases,  weak
ecovery  in  7  (41.2%)  cases,  and  no  recovery  in  3  (17.6%)
ases  (Table  2).
A  PTA  greater  than  15  dB  was  considered  a response  to
reatment,  whereas  a  PTA  less  than  15  dB  was  deemed  no
esponse  to  treatment.  The  highest  response  rate  was  found
n  the  oral  steroid  +  ozone  group  (Group  C)  (82.3%),  followed
y  the  oral  steroid  + HBOT  group  (Group  B)  (61.5%)  and  the
ral  steroid  group  (Group  A)  (50.8%).
Pearson’s  chi-squared  tests  indicated  no  signiﬁcant  dif-
erences  in  the  response  to  treatment  between  Groups  A  and
 (p  <  0.355).  Group  C  showed  a  signiﬁcantly  higher  response
ate  to  treatment  than  Group  A  (p  =  0.019).  There  were  no
igniﬁcant  differences  between  groups  B  and  C  (p  =  0.146)
Table  3).
Regarding  SDSs,  a statistically  signiﬁcant  increase  was
ound  following  treatment  in  each  of  the  three  groups
p  =  0.002),  with  no  statistically  signiﬁcant  difference  in  the
egree  of  increase  among  the  groups.
The  audiogram  curve  was  upsloping  in  16  (15%)  patients,
ownsloping  in  32  (30.1%),  ﬂat  in  25  (23.5%),  and  indicated
otal  deafness  in  33  (31.1%)  patients.  The  groups  participat-
ng  in  the  study  were  evaluated  as  showing  a  ‘response  to
reatment’  or  ‘no  response  to  treatment’  according  to  the
ypes  of  audiograms  (Table  4).
The  efﬁciency  of  steroid  treatment  in  patients  with  pro-
ound  hearing  loss  (91  dB  and  above)  was  low;  adding  HBOT
r  ozone  therapy  to  the  treatment  signiﬁcantly  contributed
o  treatment  success.
Considering  patients  with  profound  hearing  loss  only,  a
tatistically  signiﬁcant  difference  in  response  to  treatment
as  found  between  Groups  A  and  B  (p  =  0.012)  and  especially
egel’s  criteria.
Weak  recovery  No  recovery  Total
8  (12.7%)  31  (49.2%)  63
9  (34.6%)  10  (38.0%)  26
7  (41.2%)  3  (17.6%)  17
l steroid + ozone group.
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Table  3  The  groups’  response  to  the  treatment.
Groups  Response  to  treatment  No  response  to  treatment  Total
A  32  (50.8%)  31  (49.2%)  63
B 16  (61.5%)  10  (38.5%)  26
C 14  (82.4%)  3  (17.6%)  17
A, oral steroid group; B, oral steroid + hyperbaric oxygen group; C, oral steroid + ozone group.
There is response to treatment: gaining PTA above 15 dB.
There is no response to treatment: gaining PTA less than15 dB.
Table  4  The  groups’  response  to  treatment  according  to  audiogram  shape.
Audiogram  type Response  to  treatment  No  response  to  treatment
Group  A
Upsloping  9  (75.0%) 3  (25.0%)
Flat 8  (47.1%) 9  (52.9%)
Downsloping  13  (68.4%) 63  (1.6%)
Total deafness 2  (13.3%) 13  (86.7%)
Group B
Upsloping  3  (75.0%)  1  (25.0%)
Flat 3  (50.0%)  3  (50.0%)
Downsloping  7  (87.5%)  1  (12.5%)
Total deafness  2  (37.5%)  13  (62.5%)
Group C
Upsloping  --  --
Flat 1  (50.0%)  1  (50.0%)
Downsloping  5  (100.0%)  0  (0%)
Total deafness  8  (80%)  2  (20%)
A, oral steroid group; B, oral steroid + hyperbaric oxygen group; C, oral steroid + ozone group.
There is response to treatment: gaining PTA above 15 dB.
There is no response to treatment: gaining PTA less than15 dB.
Table  5  Response  to  the  treatment  in  patients  with  profound  hearing  loss.
Patients  with  profound  hearing  loss  Response  to  treatment  No  response  to  treatment  Total
Group  A  4  (19%)  17  (81%)  21
Group B  9  (60%)  6  (40%)  15
Group C  8  (80%)  2  (20%)  10
, ora
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aA, oral steroid group; B, oral steroid + hyperbaric oxygen group; C
between  Groups  A  and  C  (p  =  0.002).  No  statistically  signiﬁ-
cant  difference  was  found  between  groups  B  and  C  (Fisher’s
exact  test)  (Table  5).
Discussion
The  factors  affecting  prognosis  in  ISSNHL  include  the
patient’s  age,  existence  of  vertigo,  degree  of  initial  hear-
ing  loss,  shape  of  the  audiogram,  and  period  between  the
onset  of  hearing  loss  and  start  of  treatment.  The  degree
of  hearing  loss  is  an  important  factor  that  determines  the
response  to  treatment.  Profound  hearing  loss  of  90  dB  and
above  indicates  a  poor  prognosis.
Byl  et  al.4 reported  an  83%  rate  of  recovery  in  patients
with  mild  hearing  loss  and  22%  recovery  in  those  with  severe
hearing  loss.  In  their  placebo-controlled  study  that  included
I
b
g
al steroid + ozone group.
teroid  treatment,  Wilson  et  al.9 observed  complete  recov-
ry  in  all  of  the  patients  with  a  hearing  loss  of  40  dB  or
ess  and  in  patients  with  a  U-shaped  hearing  loss  up  to
5  dB.  However,  only  24%  of  those  with  a  ﬂat  hearing  loss
f  90  dB  and  above  appeared  to  recover;  in  addition,  none
howed  total  recovery.  Steroid  treatment  was  most  effec-
ive  in  patients  with  a  hearing  loss  of  between  40  dB  and
0  dB;  only  38%  of  these  patients  recovered  in  the  placebo
roup,  whereas  approximately  78%  recovered  in  the  steroid
roup.
In  this  study,  patients  with  profound  hearing  loss  showed
 lower  response  to  treatment  than  did  those  with  mild  loss.
n  addition,  there  was  a  statistically  signiﬁcant  difference
etween  the  oral  steroid  group  and  the  oral  steroid  +  HBOT
roup  (p  =  0.012;  Pearson’s  Chi-squared  test).  There  was
n  even  greater  difference  between  the  oral  steroid  and
 IN+Model
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ral  steroid  +  ozone  groups  (p  =  0.002;  Pearson’s  Chi-squared
est).
However,  the  efﬁciency  of  the  oral  steroid  treatment
as  low  in  patients  with  profound  hearing  loss.  In  the
resent  study,  the  response  to  treatment  with  a  total  or
lose-to-total  type  of  audiogram  conﬁguration  was  low,  in
oncordance  with  the  literature.
Recovery  in  ISSNHL  mostly  occurs  within  the  ﬁrst  2  weeks.
he  longer  the  recovery  time,  the  worse  the  prognosis.  Com-
lete  or  partial  recovery  without  treatment  is  observed  in
any  patients  (32--65%).9,10
Presently,  more  than  60  treatment  protocols  have  been
eﬁned,  but  no  precise  consensus  exists  regarding  which  is
est.  One  widely  accepted  treatment  is  steroid  treatment.
Steroids  have  several  effects  on  the  inner  ear.  They
uppress  the  immune  system  and  increase  the  microcir-
ular  current.  They  have  mineralocorticoid  effects,  and
re  thought  to  inﬂuence  ISSNHL  by  reducing  the  endolym-
hatic  pressure.  However,  the  precise  underlying  mechanism
emains  unknown.11,12
There  are  two  types  of  corticoid  receptors,  type  1  and
ype  2,  in  cochlear  and  vestibular  cells.13,14 When  glucocor-
icoid  receptors  are  activated,  a  speciﬁc  gene  expression
rogram  is  launched;  thus,  the  synthesis  of  inﬂammatory
ediators  and  cytokines  is  inhibited,  resulting  in  anti-
nﬂammatory  effects.
In  the  ﬁrst  randomized,  controlled  study  on  the  use  of
teroids  in  ISSNHL,  the  authors  compared  a  steroid  and  a
lacebo.  In  the  active  medication  group,  they  administered
rednisolone  orally  in  gradually  reduced  amounts  for  10--12
ays.  All  of  the  patients  (n  =  14)  with  moderate-frequency
earing  losses  recovered  regardless  of  the  type  of  treat-
ent.  In  patients  whose  loss  was  worse  than  90  dB  at  all
requencies,  no  difference  could  be  found  in  terms  of  recov-
ry  between  the  steroid  and  placebo  treatment  groups.  In
he  remaining  patient  population  (with  non-severe  hearing
oss  and  hearing  at  4  kHz  better  than  at  8  kHz),  signiﬁcant
ecovery  was  monitored  in  the  group  that  was  administered
teroids.  While  complete  recovery  was  achieved  in  78%  of
hose  administered  steroids,  those  administered  the  placebo
chieved  38%  partial  recovery.9 In  a  previous  prospective
andomized  study,  89%  of  a  group  administered  corticos-
eroid  treatment  recovered,  whereas  only  44%  of  the  control
roup  administered  placebo  recovered.7
HBOT  has  been  used  to  treat  inner-ear  disorders  since
he  early  1970s.15 In  the  late  1970s,  several  researchers
uggested  that  circulatory  disorders  were  the  main  reason
or  ISSNHL.  Consequently,  HBOT  became  a  comprehensive
reatment  option  for  ISSNHL.16
The  purpose  of  HBOT  in  the  treatment  of  ISSNHL  is  to
ncrease  the  partial  pressure  of  oxygen  in  the  blood  and
hen,  via  diffusion,  to  increase  the  partial  pressure  of  oxygen
n  the  inner  ear  ﬂuids  that  nourish  the  sensory  and  neural
lements  of  the  cochlea.17
Fujimura  et  al.18 claimed  that  HBOT  had  a  signiﬁcant
dditional  effect  when  used  in  combination  with  systemic
teroid  therapy  in  43  patients,  when  compared  with  51
atients  who  were  treated  with  steroids  alone.  In  patients
ith  initial  hearing  levels  of  ≥80  dB,  the  hearing  improve-
ent  rate  was  signiﬁcantly  higher  in  the  HBOT  group
han  in  the  steroid  group,  whereas  in  patients  with  ini-
ial  hearing  levels  of  <80  dB,  the  hearing  improvement
d
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ate  was  not  statistically  different  between  the  two
roups.
Alimoglu  et  al.,19 who  considered  217  patients,  adminis-
ered  an  oral  steroid  to  58  patients,  oral  steroid  +  HBOT  to
1  patients,  intratympanic  steroid  to  43  patients,  and  only
BOT  to  57  patients.  The  treatment  success  rate  was  high-
st  in  the  steroid  +  HBOT  group  (86.88%;  53/61),  followed  by
he  oral  steroid  group  (63.79%;  37/58),  the  intratympanic
teroid  group  (46.51%;  20/43),  and  the  only  HBOT  group
43.85%;  25/57).
Topuz  et  al.20 showed  that  HBOT  had  a  greater  effect  on
earing  at  low  frequencies  than  at  higher  frequencies,  par-
icularly  in  young  patients.  In  particular,  patients  younger
han  50  in  the  HBOT  group  had  better  hearing  outcomes.
Although  the  etiology  and  pathogenesis  of  ISSNHL  are  not
ompletely  understood,  vascular  causes  are  among  the  pri-
ary  underlying  etiologies.  Except  for  those  with  a  deﬁnite
ontraindication,  adding  HBOT  to  the  treatment  of  ISSNHL
s  a common  strategy.
In  our  study,  the  group  administered  steroid  treatment
xperienced  a  50.8%  treatment  response,  whereas  the
teroid  +  HBOT  group  had  a  better  response,  at  61.5%.
Although  the  patients  who  received  steroid  treatment
nd  those  who  received  HBOT  in  addition  to  steroid
reatment  showed  similar  responses  to  treatment,  the
BOT  supplement  positively  contributed  to  the  recovery  of
atients  with  severe  or  profound  hearing  loss.
Ozone  therapy  is  a  treatment  strategy  for  ISSNHL  because
t  enhances  oxygen,  glucose,  and  ATP  delivery  to  ischemic
issues,  and  leads  to  vasodilation,  increasing  the  amount
f  nitric  oxide,  stimulating  angiogenesis,  and  providing
mmunomodulation.  Hydrogen  peroxide,  a  derivative  of
eactive  oxygen  metabolites  that  generates  ozone  in  the
ody,  is  now  widely  recognized  as  an  intracellular  signaling
olecule  that  activates  a  tyrosine  kinase,  which  phosphory-
ates  a  transcription  factor  (Nuclear  Factor  kappaB;  NF-B),
hich  allows  the  synthesis  of  several  different  proteins.21--23
Recently,  a new  hypothesis  of  pathological  activation  of
he  cellular  stress  pathways  involving  NF-B in  the  cochlea
as  suggested.  Pathological  activation  of  NF-B  can  result  in
he  production  of  inﬂammatory  cytokines  and  other  stress-
elated  proteins  that  can  disrupt  the  homeostatic  balance
f  a  cell  or  tissue.24 After  ozonation,  H2O2 freely  diffuses
nto  the  cytoplasm  and  activates  speciﬁc  protein  kinases,
hich  --  by  phosphorylating  I[kappa]B  bound  to  NF-b  --  reg-
late  its  action  and  allow  migration  of  the  transcription
eterodimer  p50--p65  into  cell  nuclei,  where  it  activates
ene  expression.25 Ozone  also  induces  up-regulation  of
ntioxidant  enzymes  in  several  cell  types,  which  effec-
ively  re-equilibrates  the  oxidant--antioxidant  imbalance.25
herefore,  ozone  therapy  can  be  an  effective  method  of
reatment  according  to  the  cellular  stress  hypothesis  in
SSNHL.
In  a  study  by  Ragab  et  al.26 comprising  45  patients  with
SSNHL  at  Menouﬁya  University  Hospital  (Egypt)  between
004  and  2006,  the  study  group  (30  patients)  was  adminis-
ered  ozone  therapy  through  the  autohemotherapy  method,
hile  the  placebo  group  (15  patients)  received  sterile
istilled  water  infusions.  Both  of  the  patient  popula-
ions/groups  received  10  session  treatments  twice  a  week.
he  improvement/recovery  of  hearing  in  the  study  group
hat  received  the  ozone  therapy  proved  to  be  77%,  whereas
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the  recovery  of  hearing  in  the  placebo  group  was  40%,  a
signiﬁcant  difference.  Ozone  therapy,  by  producing  reactive
oxygen  derivatives,  causes  the  hemoglobin-oxygen  dissoci-
ation  curve  to  slide/slip  to  the  right,  thereby  causing  the
oxygen  to  be  more  easily  delivered  into  tissues;  further-
more,  this  therapy  enhances  nitric  oxide  oscillation/release,
which  is  a  powerful  vasodilator  of  endothelial  cells,  and
ﬁxes  ischemia  in  the  cochlea.  In  addition  to  these  features,
ozone  therapy  increases  antioxidant  efﬁciency  and  becomes
effective  for  the  treatment  of  ISSNHL  by  impacting  cellular
stress.26
In  another  study,  27  patients  with  tinnitus  were  admin-
istered  ozone  therapy,  26  were  administered  betahistine
treatment,  and  15  comprised  a  control  group;  a  signiﬁcant
decline  was  observed  in  average  tinnitus  disability  ques-
tionnaire  scores  and  subjective  tinnitus  scores  in  the  ozone
group  after  treatment  (p  <  0.001).  A  22.2%  recovery  rate  was
achieved  according  to  the  severity  of  tinnitus  in  patients,  a
44.4%  recovery  rate  was  achieved  according  to  the  tinni-
tus  disability  questionnaires,  and  a  40.7%  recovery  rate  was
determined  according  to  the  subjective  tinnitus  scores.27
In  this  study,  in  the  steroid  treatment  group  (Group  A),
there  was  complete  recovery  in  14  (22.2%)  cases,  partial
recovery  in  10  (15.9%),  weak  recovery  in  8  (12.7%),  and
no  recovery  in  31  (49.2%).  In  the  group  administered  ozone
therapy  in  addition  to  steroid  treatment  (Group  C),  3  cases
(17.6%)  had  total  recovery,  4  cases  had  partial  recovery
(23.5%),  and  7  cases  had  weak  recovery  (41.2%);  however,
no  recovery  was  observed  in  3  (17.6%)  of  the  cases  in  this
group.  The  highest  response  rate  to  treatment  was  in  the
steroid  +  ozone  therapy  group  (Group  C)  (82.4%),  followed  by
the  steroid  +  HBOT  group  (Group  B)  (61.5%),  and  oral  steroid
group  (Group  A)  (50.8%).
Conclusion
The  results  of  our  study  demonstrate  that  ozone  ther-
apy  signiﬁcantly  contributes  to  the  recovery  process  in
treatment  of  ISSNHL;  however,  we  believe  that  further
placebo-controlled  studies  should  be  performed  with  a
greater  number  of  patients  receiving  ozone  therapy  for  a
longer  period  and  with  a  higher  ozone  dose.
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